COVID-19 vaccine trials

On December 22, 2020 VIDO received a notice of authorization from Health Canada to initiate a Phase 1 clinical trial of the first of our two COVID-19 vaccines. This authorization enabled the clinical trial site in Halifax, the Canadian Center for Vaccinology, to recruit volunteers.

What is the vaccine being tested?

VIDO has formulated its subunit vaccine with two different adjuvants. Subunit vaccines contain purified viral proteins that are not infectious. An adjuvant is a compound that is added to a vaccine to help the vaccine produce a better immune response.

This Phase 1 trial is testing COVAC-2, a vaccine formulated with Sepivac SWE™, an adjuvant developed by Seppic and the Vaccine Formulation Institute (VFI). Sepivac SWE™ is based on technology recognized for its efficacy and safety in influenza vaccines.

What is the purpose of this Phase 1 trial?

The purpose of this trial is to demonstrate that COVAC-2 is safe to administer to people.

Who is eligible to volunteer for this Phase 1 trial?

The Phase 1 trial will involve 108 healthy adults that are 18 years of age or older. Full inclusion/exclusion criteria is posted on

How can I sign-up to volunteer for this Phase 1 trial?

The Canadian Center for Vaccinology is completing this Phase 1 trial. They are currently recruiting volunteers from their base in Halifax, Nova Scotia, Canada.

Information about the study will be posted on Additional information is posted on (NCT04702178).

What’s next?

Upon successful completion of Phase 1, the next step towards regulatory approval is to initiate Phase 2. Phase 2 clinical trials continue to examine the safety of the vaccine and also determine immunogenicity (the ability of the vaccine to induce an immune response). This study will include hundreds of volunteers at multiple sites across Canada.


We will update this page regularly – please contact us if you have additional questions. 

Updated: January 29, 2021

Contact Us